Tomas G Neilan1, Kim-Lien Nguyen2, Vlad G Zaha3, Kara W Chew4, Leavitt Morrison5, Ntobeko A B Ntusi6, Mabel Toribio7, Magid Awadalla1, Zsofia D Drobni1, Michael D Nelson8, Tricia H Burdo9, Marije Van Schalkwyk10, Paul E Sax11, Daniel J Skiest12, Karen Tashima13, Raphael J Landovitz14, Eric Daar15, Alysse G Wurcel16, Gregory K Robbins17, Robert K Bolan18, Kathleen V Fitch7, Judith S Currier4, Gerald S Bloomfield19, Patrice Desvigne-Nickens20, Pamela S Douglas21, Udo Hoffmann1, Steven K Grinspoon7, Heather Ribaudo5, Rodney Dawson22, Matthew Bidwell Goetz23, Mamta K Jain24, Alberta Warner2, Lidia S Szczepaniak25, Markella V Zanni7. 1. Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 2. Division of Cardiology, David Geffen School of Medicine at the University of California, Los Angeles and the Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA. 3. Division of Cardiovascular Medicine, Department of Medicine, Advanced Imaging Research Center, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 4. Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA. 5. Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. 6. Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa. 7. Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. 8. Applied Physiology and Advanced Imaging Laboratory, Department of Kinesiology, University of Texas at Arlington, Arlington, Texas, USA. 9. Department of Neuroscience, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA. 10. Family Clinical Research Unit, Division of Adult Infectious Diseases, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa. 11. Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 12. Department of Medicine, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA. 13. Division of Infectious Diseases, The Miriam Hospital and Alpert Medical School of Brown University, Providence, Rhode Island, USA. 14. Center for Clinical AIDS Research and Education, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA. 15. Lundquist Institute at Harbor-University of California, Los Angeles Medical Center and David Geffen School of Medicine at the University of Los Angeles, Los Angeles, California, USA. 16. Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA. 17. Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. 18. Los Angeles Lesbian Gay Bisexual Transgender Center, Los Angeles, California, USA. 19. Duke Clinical Research Institute, Duke Global Health Institute, Department of Medicine, Duke University, Durham, North Carolina, USA. 20. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. 21. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA. 22. Division of Pulmonology and Department of Medicine, University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa. 23. Infectious Diseases Section, Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA. 24. Division of Infectious Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 25. Biomedical Research Consulting in Magnetic Resonance Spectroscopy, Albuquerque, New Mexico, USA.
Abstract
BACKGROUND:People with human immunodeficiency virus (PWH) face increased risks for heart failure and adverse heart failure outcomes. Myocardial steatosis predisposes to diastolic dysfunction, a heart failure precursor. We aimed to characterize myocardial steatosis and associated potential risk factors among a subset of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) participants. METHODS:Eighty-two PWH without known heart failure successfully underwentcardiovascular magnetic resonance spectroscopy, yielding data on intramyocardial triglyceride (IMTG) content (a continuous marker for myocardial steatosis extent). Logistic regression models were applied to investigate associations between select clinical characteristics and odds of increased or markedly increased IMTG content. RESULTS:Median (Q1, Q3) IMTG content was 0.59% (0.28%, 1.15%). IMTG content was increased (> 0.5%) among 52% and markedly increased (> 1.5%) among 22% of participants. Parameters associated with increased IMTG content included age (P = .013), body mass index (BMI) ≥ 25 kg/m2 (P = .055), history of intravenous drug use (IVDU) (P = .033), and nadir CD4 count < 350 cells/mm³ (P = .055). Age and BMI ≥ 25 kg/m2 were additionally associated with increased odds of markedly increased IMTG content (P = .049 and P = .046, respectively). CONCLUSIONS: A substantial proportion of antiretroviral therapy-treated PWH exhibited myocardial steatosis. Age, BMI ≥ 25 kg/m2, low nadir CD4 count, and history of IVDU emerged as possible risk factors for myocardial steatosis in this group. CLINICAL TRIALS REGISTRATION: NCT02344290; NCT03238755.
RCT Entities:
BACKGROUND:People with human immunodeficiency virus (PWH) face increased risks for heart failure and adverse heart failure outcomes. Myocardial steatosis predisposes to diastolic dysfunction, a heart failure precursor. We aimed to characterize myocardial steatosis and associated potential risk factors among a subset of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) participants. METHODS: Eighty-two PWH without known heart failure successfully underwent cardiovascular magnetic resonance spectroscopy, yielding data on intramyocardial triglyceride (IMTG) content (a continuous marker for myocardial steatosis extent). Logistic regression models were applied to investigate associations between select clinical characteristics and odds of increased or markedly increased IMTG content. RESULTS: Median (Q1, Q3) IMTG content was 0.59% (0.28%, 1.15%). IMTG content was increased (> 0.5%) among 52% and markedly increased (> 1.5%) among 22% of participants. Parameters associated with increased IMTG content included age (P = .013), body mass index (BMI) ≥ 25 kg/m2 (P = .055), history of intravenous drug use (IVDU) (P = .033), and nadir CD4 count < 350 cells/mm³ (P = .055). Age and BMI ≥ 25 kg/m2 were additionally associated with increased odds of markedly increased IMTG content (P = .049 and P = .046, respectively). CONCLUSIONS: A substantial proportion of antiretroviral therapy-treated PWH exhibited myocardial steatosis. Age, BMI ≥ 25 kg/m2, low nadir CD4 count, and history of IVDU emerged as possible risk factors for myocardial steatosis in this group. CLINICAL TRIALS REGISTRATION: NCT02344290; NCT03238755.
Authors: Adeel A Butt; Chung-Chou Chang; Lewis Kuller; Matthew Bidwell Goetz; David Leaf; David Rimland; Cynthia L Gibert; Krisann K Oursler; Maria C Rodriguez-Barradas; Joseph Lim; Lewis E Kazis; Stephen Gottlieb; Amy C Justice; Matthew S Freiberg Journal: Arch Intern Med Date: 2011-04-25
Authors: Steven K Grinspoon; Kathleen V Fitch; Edgar Turner Overton; Carl J Fichtenbaum; Markella V Zanni; Judith A Aberg; Carlos Malvestutto; Michael T Lu; Judith S Currier; Craig A Sponseller; Myron Waclawiw; Beverly Alston-Smith; Katharine Cooper-Arnold; Karin L Klingman; Patrice Desvigne-Nickens; Udo Hoffmann; Heather J Ribaudo; Pamela S Douglas Journal: Am Heart J Date: 2019-03-04 Impact factor: 4.749
Authors: Janet Wei; Michael D Nelson; Edward W Szczepaniak; Laura Smith; Puja K Mehta; Louise E J Thomson; Daniel S Berman; Debiao Li; C Noel Bairey Merz; Lidia S Szczepaniak Journal: Am J Physiol Heart Circ Physiol Date: 2015-10-30 Impact factor: 4.733
Authors: Michael D Nelson; Lidia S Szczepaniak; Troy M LaBounty; Edward Szczepaniak; Debiao Li; Mourad Tighiouart; Quanlin Li; Rohan Dharmakumar; Gregg Sannes; Zhaoyang Fan; Roya Yumul; W David Hardy; Antonio Hernandez Conte Journal: JACC Cardiovasc Imaging Date: 2014-11-10
Authors: Diana K Thiara; Chia Ying Liu; Fabio Raman; Sabrina Mangat; Julia B Purdy; Horacio A Duarte; Nancyanne Schmidt; Jamie Hur; Christopher T Sibley; David A Bluemke; Colleen Hadigan Journal: J Infect Dis Date: 2015-05-11 Impact factor: 5.226
Authors: Jonathan M McGavock; Ildiko Lingvay; Ivana Zib; Tommy Tillery; Naomi Salas; Roger Unger; Benjamin D Levine; Philip Raskin; Ronald G Victor; Lidia S Szczepaniak Journal: Circulation Date: 2007-08-13 Impact factor: 29.690
Authors: Paul E Sax; Kristine M Erlandson; Jordan E Lake; Grace A Mccomsey; Chloe Orkin; Stefan Esser; Todd T Brown; Jürgen K Rockstroh; Xuelian Wei; Christoph C Carter; Lijie Zhong; Diana M Brainard; Kathleen Melbourne; Moupali Das; Hans-Jürgen Stellbrink; Frank A Post; Laura Waters; John R Koethe Journal: Clin Infect Dis Date: 2020-09-12 Impact factor: 9.079
Authors: Suman Srinivasa; Teressa S Thomas; Meghan N Feldpausch; Gail K Adler; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2021-11-19 Impact factor: 5.958